R&D News | pharmaphorum

News

Celltrion trials infliximab biosimilar in recovering COVID-1...

South Korea’s Celltrion Healthcare has begun a UK trial of its infliximab biosimilar to see if the drug can accelerate recovery from symptoms of COVID-19.

News

AbbVie forges $3.9 billion oncology alliance with Genmab

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgk

News

J&J brings forward start of COVID-19 vaccine trial to next m...

Johnson & Johnson has announced it has brought forward the start of its COVID-19 vaccine by around two months to mid-July.

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Sanofi hands back gene therapies to Oxford Biomedica

Oxford Biomedica’s long-running alliance with Sanofi over a pair of gene therapies for ophthalmic diseases has come to an end, after an internal review by the French drugmaker.

News

Lundbeck announces plans to cut a fifth of R&D workforce

Lundbeck has announced plans to cut its research and development team, which could lead to a reduction of up to 160 jobs from an 800-strong department.

News

Close-up image of a firm handshake between two colleagues

AstraZeneca ‘probably couldn’t run Gilead any better:’ analy...

AstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to be that there would anyway be little value in such a

Celltrion trials infliximab biosimilar in recovering COVID-1...

AbbVie forges $3.9 billion oncology alliance with Genmab

J&J brings forward start of COVID-19 vaccine trial to next m...

Sanofi hands back gene therapies to Oxford Biomedica

Lundbeck announces plans to cut a fifth of R&D workforce

AstraZeneca ‘probably couldn’t run Gilead any better:’ analy...

Hengrui gets world-first okay for platelet drug hetrombopag

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks